US senators seek answers in Plan B flap; group declares fight not over
This article was originally published in SRA
Executive Summary
A group of US senators has demanded to know the rationale and scientific data Health and Human Services Secretary Kathleen Sebelius used to base her 7 December decision to block the US FDA's approval to permit Teva to market its single-pill emergency contraceptive Plan B One-Step (1.5 mg levonorgestrel tablet) as an over-the-counter product with no age restrictions1,2.